Trials / Completed
CompletedNCT03582267
The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Texas Christian University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
Nutrition interventions may present a safe and relatively risk free intervention for protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the brain's development and structural integrity. The goal of this study is to determine if supplementation with DHA attenuates blood biomarkers of repetitive head trauma linked to sub-concussive impacts sustained in rugby participation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Docosahexaenoic Acid (DHA) | Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period. |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2018-08-01
- Completion
- 2019-08-01
- First posted
- 2018-07-10
- Last updated
- 2019-09-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03582267. Inclusion in this directory is not an endorsement.